when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

BOEHRINGER INGELHEIM · news · pharmadog

← back to BOEHRINGER INGELHEIM

News mentioning BOEHRINGER INGELHEIM

50 stories

3dSTAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and morestat

4d3 takeaways from a European obesity scientific meetingbiopharma dive

4dBMS reports liver injury events in lung disease program, with key readout nearbiospace

4dZealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againbiospace

4d#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesityendpoints

4dZealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3fiercebiotech

10dLegend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitendpoints

12d9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europebiopharma dive

12dBoehringer adds $250M to value of Variant pact by expanding into cardiovascular diseasefiercebiotech

13dViking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsbiospace

13dBoehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenicsbiospace

14dBoehringer, Envisagenics sign $1B multi-target oncology collaborationfiercebiotech

18dNovo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugsbiospace

18dRare EGFR mutation increases lung cancer risk 62 times in never smokersfiercebiotech

20dWCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightbiopharma dive

Sep 3, 26Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readoutfiercebiotech

Sep 2, 26Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsbiospace

Sep 1, 26Roche finds another oncology gem in Asia with $1.5B B cell disease partnershipbiospace

Sep 1, 26Roche inks $1.53B deal for Simcere’s B-cell-targeting antibodyfiercebiotech

Aug 24, 26Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’biospace

Aug 20, 26Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’fiercebiotech

Aug 20, 26Why pediatric rare oncology outperforms in a volatile biotech marketbiospace

Aug 18, 26Leo Pharma buys rare skin disease drug in $435M dealbiopharma dive

Aug 18, 26LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugbiospace

Aug 17, 26Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodfiercebiotech

Aug 17, 26Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vaguefiercebiotech

Aug 13, 26Meet Motivista: Click Therapeutics debuts first-of-its-kind schizophrenia digital therapeuticfiercebiotech

Aug 13, 26Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionfiercebiotech

Aug 11, 26After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’biospace

Aug 5, 26A COPD drug from China draws $115M in venture fundingbiopharma dive

← prevpage 1 of 2next →